[生物书合集].Advances.in.Clinical.TBiostatisti

[生物书合集].Advances.in.Clinical.TBiostatisti

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
use of CRML must be preceded by an initial stage whose design does not require maximum likelihood estimation. This stage might be designed according to Bayesian principles (e.g., by original CRM) or by use of more traditional up-and-down schemes based on a modified Fibonacci sequence. Once at least one patient manifests and one patient is treated without DLT, the first stage can be terminated and subsequent dose escalations can be determined through the use of CRML. Since CRML is inherently non-Bayesian, it will not be discussed further in this chapter. Instead we refer interested readers to O’Quigley and Shen (1996) and Kramar et al. (1999) for details regarding the implementation of CRML. 3.2. Delayed Response Since cancer patients often exhibit delayed response to treatment, the time required to definitively evaluate treatment response can be longer than the average time between successive patient accruals. Consequently, new patients frequently become available to the study before the
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 06/13/2011 for the course PHYSICS 101 taught by Professor Shu during the Spring '11 term at FIU.

Ask a homework question - tutors are online